In 2007, Petridou et al. found that serum adiponectin was not significantly different in patients with lung cancer compared with controls but that it was significantly lower in patients at advanced disease stages, suggesting that adiponectin could be a potential marker for lung cancer progression[3].Pei et al. then undertook a meta-analysis to exploit the causal relevance of circulating adiponectin with cancer; their findings demonstrated that genetically higher circulating adiponectin conferred a protective effect against lung cancer but a risk for colorectal cancer[29]. The gene discussed is ADIPOQ; the disease is lung cancer.